title: Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.
abstract: Recovery from acute hepatitis B virus (HBV) infection requires a broad, vigorous T-cell response, which is enhanced in mice when chemokine receptor 5 (CCR5) is missing. To test the hypothesis that production of a nonfunctional CCR5 (CCR5Delta32 [a functionally null allele containing a 32-bp deletion]) increases the likelihood of recovery from hepatitis B in humans, we studied 526 persons from three cohorts in which one person with HBV persistence was matched to two persons who recovered from an HBV infection. Recovery or persistence was determined prior to availability of lamivudine. We determined genotypes for CCR5Delta32 and for polymorphisms in the CCR5 promoter and in coding regions of the neighboring genes, chemokine receptor 2 (CCR2) and chemokine receptor-like 2 (CCRL2). Allele and haplotype frequencies were compared among the 190 persons with viral recovery and the 336 with persistence by use of conditional logistic regression. CCR5Delta32 reduced the risk of developing a persistent HBV infection by nearly half (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.33 to 0.83; P = 0.006). This association was virtually identical in persons with and without a concomitant human immunodeficiency virus infection. Of the nine individuals who were homozygous for the deletion, eight recovered from infection (OR, 0.25; 95% CI, 0.03 to 1.99; P = 0.19). None of the other neighboring polymorphisms examined were associated with HBV outcome. These data demonstrate a protective effect of CCR5Delta32 in recovery from an HBV infection, provide genetic epidemiological evidence for a role of CCR5 in the immune response to HBV, and suggest a potential therapeutic treatment for patients persistently infected with HBV.
authors.affiliation: Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: Chloe L
authors.initials: CL
authors.lastname: Thio
authors.forename: Jacquie
authors.initials: J
authors.lastname: Astemborski
authors.forename: Arman
authors.initials: A
authors.lastname: Bashirova
authors.forename: Timothy
authors.initials: T
authors.lastname: Mosbruger
authors.forename: Spencer
authors.initials: S
authors.lastname: Greer
authors.forename: Mallory D
authors.initials: MD
authors.lastname: Witt
authors.forename: James J
authors.initials: JJ
authors.lastname: Goedert
authors.forename: Margaret
authors.initials: M
authors.lastname: Hilgartner
authors.forename: Audrey
authors.initials: A
authors.lastname: Majeske
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: O'Brien
authors.forename: David L
authors.initials: DL
authors.lastname: Thomas
authors.forename: Mary
authors.initials: M
authors.lastname: Carrington
mesh_terms: D000328:Adult; D000483:Alleles; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006515:Hepatitis B virus / Q000472:pathogenicity*; D019694:Hepatitis B, Chronic / Q000235:genetics* / Q000276:immunology* / Q000821:virology; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D019713:Receptors, CCR5 / Q000172:deficiency / Q000235:genetics* / Q000502:physiology*
chemical_list: D019713:Receptors, CCR5